메뉴 건너뛰기




Volumn 61, Issue 3, 2009, Pages 252-266

Guidelines in RA treatment: Concepts on safety and recomendations using anti-TNF-α inhibitors;Recomendaciones para el tratamiento médico de la artritis reumatoide: Actualización sobre la seguridad de los antagonistas del factor de necrosis tumoral alfa

(12)  Díaz Jouanen, Efraín a,n,o   Abud Mendoza, Carlos b,o   Garza Elizondo, Mario Alberto d,o   Medrano Ramírez, Gabriel c,o   Burgos Vargas, Rubén e,o   Orozco Alcalá, José Javier f,o   Pacheco Tena, César Francisco g,o   Pineda, Carlos h,o   Pozos Espíndola, Juan Carlos i,o   Ramos Niembro, Francisco j,o   Robles San Román, Manuel k,o   Santana Sahagún, Jesús Ernesto l,m,o  


Author keywords

(TNF ) antagonists; Autoimmunity; Cancer; Cardiovascular risk; Immunization; Infections; Lactation; Pregnancy; Rheumatoid arthritis; Surgery

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 70349202394     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (3)

References (100)
  • 2
    • 33747008410 scopus 로고    scopus 로고
    • Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Results from the British Society for Rheumatology Biologics Register
    • British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, and Symmons, on behalf of the British Society for Rheumatology Biologics Register
    • Dixon WG, Watson K, Lunt M, Hyrich KL. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, and Symmons, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376
    • (2006) Arthritis Rheum , vol.54 , pp. 2368-2376
    • Dixon, W.G.1    Watson, K.2    Lunt, M.3    Hyrich, K.L.4
  • 3
    • 34447521875 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor-therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    • Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor-therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-1764
    • (2007) Arthritis Rheum , vol.56 , pp. 1754-1764
    • Schneeweiss, S.1    Setoguchi, S.2    Weinblatt, M.E.3    Katz, J.N.4    Avorn, J.5    Sax, P.E.6
  • 4
    • 34247218183 scopus 로고    scopus 로고
    • Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor-antagonists
    • DOI 10.1002/art.22504
    • Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor-antagonists. Arthritis Rheum 2007; 56: 1125-1133 (Pubitemid 46608637)
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.4 , pp. 1125-1133
    • Curtis, J.R.1    Patkar, N.2    Xie, A.3    Martin, C.4    Allison, J.J.5    Saag, M.6    Shatin, D.7    Saag, K.G.8
  • 6
    • 33750723407 scopus 로고    scopus 로고
    • Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis
    • letter
    • Costenbader KH, Glass R, Cui J, Shadick N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis JAMA 2006; 296: 2201. (letter).
    • (2006) JAMA , vol.296 , pp. 2201
    • Costenbader, K.H.1    Glass, R.2    Cui, J.3    Shadick, N.4
  • 7
    • 34447304631 scopus 로고    scopus 로고
    • Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
    • DOI 10.1093/rheumatology/kem076
    • Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46: 1157-1160 (Pubitemid 47050621)
    • (2007) Rheumatology , vol.46 , Issue.7 , pp. 1157-1160
    • Bernatsky, S.1    Hudson, M.2    Suissa, S.3
  • 9
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • DOI 10.1001/jama.295.19.2275
    • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285 (Pubitemid 43736578)
    • (2006) Journal of the American Medical Association , vol.295 , Issue.19 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3    Buchan, I.4    Matteson, E.L.5    Montori, V.6
  • 11
    • 40349096096 scopus 로고    scopus 로고
    • The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
    • DOI 10.1097/BOR.0b013e3282f4b392, PII 0000228120080300000005
    • Askling J, Dixon W. The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138-144 (Pubitemid 351339884)
    • (2008) Current Opinion in Rheumatology , vol.20 , Issue.2 , pp. 138-144
    • Askling, J.1    Dixon, W.2
  • 12
    • 38449122780 scopus 로고    scopus 로고
    • TNF antagonist safety in rheumatoid arthritis: Updated evidence from observational registries
    • Nasir A, Greenberg JD, TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries. Bull NYU Hosp Jt Dis 2006; 65: 178-181
    • (2006) Bull NYU Hosp Jt Dis , vol.65 , pp. 178-181
    • Nasir, A.1    Greenberg, J.D.2
  • 14
    • 84869605240 scopus 로고    scopus 로고
    • Available in
    • Available in: http://www.fda.gov/cder/drug/InfoSheets/HCP/TNF- blockersHCP.html
  • 17
    • 34250179530 scopus 로고    scopus 로고
    • Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection
    • Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, and Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353-1355 (Pubitemid 46898121)
    • (2007) Journal of Rheumatology , vol.34 , Issue.6 , pp. 1353-1355
    • Linardaki, G.1    Katsarou, O.2    Ioannidou, P.3    Karafoulidou, A.4    Boki, K.5
  • 18
    • 33746652902 scopus 로고    scopus 로고
    • Hepatitis B and C virus infections and anti-tumor necrosis factor a therapy: Guidelines for clinical approach
    • DOI 10.1111/j.1440-1746.2006.04559.x
    • Nathan DM, Angus PW and Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor a therapy: Guidelines for clinical approach. J Gastroenterol Hepatolol 2006; 21: 1366-1371 (Pubitemid 44154702)
    • (2006) Journal of Gastroenterology and Hepatology , vol.21 , Issue.9 , pp. 1366-1371
    • Nathan, D.M.1    Angus, P.W.2    Gibson, P.R.3
  • 21
    • 0018110856 scopus 로고
    • Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
    • Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691-696
    • (1978) J Chronic Dis , vol.31 , pp. 691-696
    • Isomaki, H.A.1    Hakulinen, T.2    Joutsenlahti, U.3
  • 22
    • 0021967162 scopus 로고
    • Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort
    • DOI 10.1016/0002-9343(85)90246-3
    • Katusic S, Beard CM, Kurland LT, Weiss JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78(1A): 50-55 (Pubitemid 15167366)
    • (1985) American Journal of Medicine , vol.78 , Issue.1 A , pp. 50-55
    • Katusic, S.1    Beard, C.M.2    Kurland, L.T.3
  • 23
    • 0032543858 scopus 로고    scopus 로고
    • Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study
    • Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180-181 (Pubitemid 28325543)
    • (1998) British Medical Journal , vol.317 , Issue.7152 , pp. 180-181
    • Baecklund, E.1    Ekbom, A.2    Sparen, P.3    Feltelius, N.4    Klareskog, L.5
  • 24
    • 0034913946 scopus 로고    scopus 로고
    • Review article: The risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment
    • DOI 10.1046/j.1365-2036.2001.01023.x
    • Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001; 15: 1101-1108 (Pubitemid 32675443)
    • (2001) Alimentary Pharmacology and Therapeutics , vol.15 , Issue.8 , pp. 1101-1108
    • Aithal, G.P.1    Mansfield, J.C.2
  • 25
    • 24644495220 scopus 로고    scopus 로고
    • The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents
    • DOI 10.1016/j.critrevonc.2005.02.004, PII S1040842805000958
    • Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 2005; 56: 169-178 (Pubitemid 41278655)
    • (2005) Critical Reviews in Oncology/Hematology , vol.56 , Issue.1 SPEC. ISS , pp. 169-178
    • Kwon, J.H.1    Farrell, R.J.2
  • 26
    • 2642554059 scopus 로고    scopus 로고
    • Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients
    • DOI 10.1002/art.20311
    • Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and antitumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-1751 (Pubitemid 38725085)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.6 , pp. 1740-1751
    • Wolfe, F.1    Michaud, K.2
  • 27
    • 0036900501 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration
    • Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158
    • (2002) Arthritis Rheum , vol.46 , pp. 3151-3158
    • Brown, S.L.1    Greene, M.H.2    Gershon, S.K.3    Edwards, E.T.4    Braun, M.M.5
  • 29
    • 17644374819 scopus 로고    scopus 로고
    • Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
    • DOI 10.1136/ard.2004.030528
    • Geborek P, Bladstrom A, Turesson C, Gulfe A, Peterson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703. (Pubitemid 40559295)
    • (2005) Annals of the Rheumatic Diseases , vol.64 , Issue.5 , pp. 699-703
    • Geborek, P.1    Bladstrom, A.2    Turesson, C.3    Gulfe, A.4    Petersson, I.F.5    Saxne, T.6    Olsson, H.7    Jacobsson, L.T.H.8
  • 31
    • 34248547187 scopus 로고    scopus 로고
    • The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation
    • DOI 10.1002/art.22579
    • Wolfe F, Michaud K. The effect of methotrexate and anti-tumour necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-1439 (Pubitemid 46764070)
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.5 , pp. 1433-1439
    • Wolfe, F.1    Michaud, K.2
  • 32
    • 0037225374 scopus 로고    scopus 로고
    • Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis
    • Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40. (Pubitemid 36077769)
    • (2003) Journal of Rheumatology , vol.30 , Issue.1 , pp. 36-40
    • Wolfe, F.1    Freundlich, B.2    Straus, W.L.3
  • 33
    • 16844372053 scopus 로고    scopus 로고
    • TNF-a, rheumatoid arthritis, and heart failure: A rheumatological dilemma
    • DOI 10.1016/j.autrev.2004.09.004
    • Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-a, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4: 153-161 (Pubitemid 40488744)
    • (2005) Autoimmunity Reviews , vol.4 , Issue.3 , pp. 153-161
    • Sarzi-Puttini, P.1    Atzeni, F.2    Shoenfeld, Y.3    Ferraccioli, G.4
  • 34
    • 0035676529 scopus 로고    scopus 로고
    • High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors
    • DOI 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#
    • Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745 (Pubitemid 34016192)
    • (2001) Arthritis and Rheumatism , vol.44 , Issue.12 , pp. 2737-2745
    • Del Rincon, I.1    Williams, K.2    Stern, M.P.3    Freeman, G.L.4    Escalante, A.5
  • 35
    • 0036229685 scopus 로고    scopus 로고
    • Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?
    • Review
    • Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [Review]. Arthritis Rheum 2002; 46: 862-873
    • (2002) Arthritis Rheum , vol.46 , pp. 862-873
    • Van Doornum, S.1    McColl, G.2    Wicks, I.P.3
  • 37
    • 0037643388 scopus 로고    scopus 로고
    • All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database
    • Watson DJ, Rhodes T, Guess HA. All- cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-1202 (Pubitemid 36666340)
    • (2003) Journal of Rheumatology , vol.30 , Issue.6 , pp. 1196-1202
    • Watson, D.J.1    Rhodes, T.2    Guess, H.A.3
  • 38
    • 0025286817 scopus 로고
    • Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
    • Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241 (Pubitemid 20225044)
    • (1990) New England Journal of Medicine , vol.323 , Issue.4 , pp. 236-241
    • Levine, B.1    Kalman, J.2    Mayer, L.3    Fillit, H.M.4    Packer, M.5
  • 39
    • 28544447858 scopus 로고    scopus 로고
    • Disease modification and cardiovascular risk reduction: Two sides of the same coin?
    • Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44: 1473-1482
    • (2005) Rheumatology (Oxford) , vol.44 , pp. 1473-1482
    • Hall, F.C.1    Dalbeth, N.2
  • 40
    • 40549134937 scopus 로고    scopus 로고
    • Does tumor necrosis factor a inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    • Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor a inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58: 667-677
    • (2008) Arthritis Rheum , vol.58 , pp. 667-677
    • Listing, J.1    Strangfeld, A.2    Kekow, J.3    Schneider, M.4    Kapelle, A.5    Wassenberg, S.6
  • 41
    • 11144355760 scopus 로고    scopus 로고
    • Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
    • Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).Circulation 2004; 109: 1594-1602
    • (2004) Circulation , vol.109 , pp. 1594-1602
    • Mann, D.L.1    McMurray, J.J.2    Packer, M.3    Swedberg, K.4    Borer, J.S.5    Colucci, W.S.6
  • 42
    • 0038755661 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial
    • DOI 10.1161/01.CIR.0000077913.60364.D2
    • Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140 (Pubitemid 36793081)
    • (2003) Circulation , vol.107 , Issue.25 , pp. 3133-3140
    • Chung, E.S.1    Packer, M.2    Lo, K.H.3    Fasanmade, A.A.4    Willerson, J.T.5
  • 44
    • 38149029249 scopus 로고    scopus 로고
    • COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal antiinflammatory drugs
    • Warner TD, Mitchell JA, COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal antiinflammatory drugs. Lancet 2008; 371: 270-273
    • (2008) Lancet , vol.371 , pp. 270-273
    • Warner, T.D.1    Mitchell, J.A.2
  • 45
    • 16644398295 scopus 로고    scopus 로고
    • Serious infections associated with anticytokine therapies in the rheumatic diseases
    • Giles JT, Barthon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320-334
    • (2004) J Intensive Care Med , vol.19 , pp. 320-334
    • Giles, J.T.1    Barthon, J.M.2
  • 46
    • 0031750237 scopus 로고    scopus 로고
    • The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis
    • DOI 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G
    • Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1072-1082 (Pubitemid 28265410)
    • (1998) Arthritis and Rheumatism , vol.41 , Issue.6 , pp. 1072-1082
    • Wolfe, F.1    Zwillich, S.H.2
  • 47
    • 0035089096 scopus 로고    scopus 로고
    • Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery
    • DOI 10.1136/ard.60.3.214
    • Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Ann Rheum Dis 2001; 60: 214-217 (Pubitemid 32260601)
    • (2001) Annals of the Rheumatic Diseases , vol.60 , Issue.3 , pp. 214-217
    • Grennan, D.M.1    Gray, J.2    Loudon, J.3    Fear, S.4
  • 48
    • 0021630151 scopus 로고
    • Postoperative wound infection in rheumatoid arthritis surgery
    • DOI 10.1007/BF02032339
    • Hamalainen M, Raunio P, von Essen R. Postoperative wound infection in rheumatoid arthritis surgery. Clin Rheumatol 1984; 3: 329-335 (Pubitemid 15072114)
    • (1984) Clinical Rheumatology , vol.3 , Issue.3 , pp. 329-335
    • Hamalainen, M.1    Raunio, P.2    Von Essen, R.3
  • 49
    • 66749134302 scopus 로고    scopus 로고
    • Incidence and risk factors for prosthetic joint infections in patients with rheumatoid arthritis following total knee and total hip replacement
    • abstract
    • Bongartz T, Halligan CS, Osmon DR, Hanssen AD, Bamlet WR, Matteson EL. Incidence and risk factors for prosthetic joint infections in patients with rheumatoid arthritis following total knee and total hip replacement Arthritis Rheum 2005; 52:(Suppl. 9): 1449. [abstract].
    • (2005) Arthritis Rheum , vol.52 , Issue.SUPPL. 9 , pp. 1449
    • Bongartz, T.1    Halligan, C.S.2    Osmon, D.R.3    Hanssen, A.D.4    Bamlet, W.R.5    Matteson, E.L.6
  • 50
    • 34247338122 scopus 로고    scopus 로고
    • Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study
    • den Broeder A, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34: 689-695 (Pubitemid 46641372)
    • (2007) Journal of Rheumatology , vol.34 , Issue.4 , pp. 689-695
    • Den Broeder, A.A.1    Creemers, M.C.W.2    Fransen, J.3    De Jong, E.4    De Rooij, D.-J.R.5    Wymenga, A.6    De Waal-Malefijt, M.7    Van Den Hoogen, F.H.J.8
  • 51
    • 3342881856 scopus 로고    scopus 로고
    • Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy
    • Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopedic foot and ankle surgery during tumor necrosis-alpha inhibition therapy. Foot Ankle Int 2004; 25: 331-335 (Pubitemid 39096154)
    • (2004) Foot and Ankle International , vol.25 , Issue.5 , pp. 331-335
    • Bibbo, C.1    Goldberg, J.W.2
  • 52
    • 33645904180 scopus 로고    scopus 로고
    • Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis
    • Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55: 333-337
    • (2006) Arthritis Rheum , vol.55 , pp. 333-337
    • Giles, J.T.1    Bartlett, S.J.2    Gelber, A.C.3    Nanda, S.4    Fontaine, K.5    Ruffing, V.6
  • 53
    • 33747008410 scopus 로고    scopus 로고
    • Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Register
    • Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Register. Arthritis Rheum 2006; 54: 2368-2376
    • (2006) Arthritis Rheum , vol.54 , pp. 2368-2376
    • Dixon, W.G.1    Watson, K.2    Lunt, M.3    Hyrich, K.L.4    Silman, A.J.5    Symmons, D.P.6
  • 54
    • 34047163955 scopus 로고    scopus 로고
    • Patients with rheumatoid arthritis undergoing surgery: How should we deal with antir heumatic treatment?
    • Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antir heumatic treatment? Semin Arthritis Rheum 2007; 36: 278-286
    • (2007) Semin Arthritis Rheum , vol.36 , pp. 278-286
    • Pieringer, H.1    Stuby, U.2    Biesenbach, G.3
  • 56
    • 27244434053 scopus 로고    scopus 로고
    • Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR)
    • Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 2005; 72(Suppl. 1): S49-S50.
    • (2005) Joint Bone Spine , vol.72 , Issue.1
    • Pham, T.1    Claudepierre, P.2    Deprez, X.3    Fautrel, B.4    Goupille, P.5    Hilliquin, P.6
  • 57
    • 0028143211 scopus 로고
    • Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis
    • Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344; 1105-1110
    • (1994) Lancet , vol.344 , pp. 1105-1110
    • Elliott, M.J.1    Maini, R.N.2    Feldmann, M.3    Kalden, J.R.4    Antoni, C.5    Smolen, J.S.6
  • 58
    • 0033763979 scopus 로고    scopus 로고
    • Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a:? Findings in open-label and randomized placebo-controlled trials
    • DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D
    • Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a:? findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-2390 (Pubitemid 30829259)
    • (2000) Arthritis and Rheumatism , vol.43 , Issue.11 , pp. 2383-2390
    • Charles, P.J.1    Smeenk, R.J.T.2    De Jong, J.3    Feldmann, M.4    Maini, R.N.5
  • 59
    • 84869603666 scopus 로고    scopus 로고
    • Autoinmunidad, enfermedades autoinmunes y otros procesos mediados inmunológicamente, asociados con el empleo de los inhibidores del factor de necrosis tumoral alfa
    • Ramos NF, Orozco AJ (eds.)México: Elsevier-Masson-Doyma, S.A.
    • Ramos NF. Autoinmunidad, enfermedades autoinmunes y otros procesos mediados inmunológicamente, asociados con el empleo de los inhibidores del factor de necrosis tumoral alfa. En: Terapia biológica en las enfermedades reumáticas. Ramos NF, Orozco AJ (eds.). México: Elsevier-Masson-Doyma, S.A.: 2006, p. 307-343
    • (2006) Terapia Biológica en Las Enfermedades Reumáticas , pp. 307-343
    • Ramos, N.F.1
  • 61
    • 23644452510 scopus 로고    scopus 로고
    • Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept
    • DOI 10.1002/art.21197
    • Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-2451 (Pubitemid 41117431)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.8 , pp. 2447-2451
    • Braun, J.1    Baraliakos, X.2    Listing, J.3    Sieper, J.4
  • 62
    • 0842331999 scopus 로고    scopus 로고
    • Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis
    • DOI 10.1016/S0161-6420(03)00721-8
    • Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352-356 (Pubitemid 38183244)
    • (2004) Ophthalmology , vol.111 , Issue.2 , pp. 352-356
    • Murphy, C.C.1    Ayliffe, W.H.2    Booth, A.3    Makanjuola, D.4    Andrews, P.A.5    Jayne, D.6
  • 64
    • 0037478882 scopus 로고    scopus 로고
    • Infliximab in the treatment of refractory posterior uveitis
    • DOI 10.1016/S0161-6420(03)00406-8
    • Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449-1453 (Pubitemid 36842488)
    • (2003) Ophthalmology , vol.110 , Issue.7 , pp. 1449-1453
    • Joseph, A.1    Raj, D.2    Dua, H.S.3    Powell, P.T.4    Lanyon, P.C.5    Powell, R.J.6
  • 65
    • 23044509893 scopus 로고    scopus 로고
    • Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients
    • Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin AP, Guillevin L. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005; 34: 916-918
    • (2005) Presse Med , vol.34 , pp. 916-918
    • Lanthier, N.1    Parc, C.2    Scavennec, R.3    Dhôte, R.4    Brézin, A.P.5    Guillevin, L.6
  • 67
    • 0042887352 scopus 로고    scopus 로고
    • Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease?
    • Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-834
    • (2003) Ann Rheum Dis , vol.62 , pp. 829-834
    • Baeten, D.1    Kruithof, E.2    Van Den Bosch, F.3    Van Den Bossche, N.4    Herssens, A.5    Mielants, H.6
  • 71
    • 33846999640 scopus 로고    scopus 로고
    • Tumor necrosis factor-an inhibition and palmoplantar pustulosis: Janus- Faced therapy?
    • Dutz JP. Tumor necrosis factor-an inhibition and palmoplantar pustulosis: Janus- faced therapy? J Rheumatol 2007; 34: 247-249
    • (2007) J Rheumatol , vol.34 , pp. 247-249
    • Dutz, J.P.1
  • 72
    • 48849085127 scopus 로고    scopus 로고
    • Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register
    • Apr 2. [Epub ahead of print]
    • Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2008 Apr 2. [Epub ahead of print].
    • (2008) Ann Rheum Dis
    • Harrison, M.J.1    Dixon, W.G.2    Watson, K.D.3    King, Y.4    Groves, R.5    Hyrich, K.L.6
  • 73
    • 70349221805 scopus 로고
    • Springhouse, Pennsylvania: Springhouse Corp.
    • Physician's Drug Handbook. 5th. Ed. Springhouse, Pennsylvania: Springhouse Corp.; 1993, p. vii.
    • (1993) Physician's Drug Handbook. 5th. Ed.
  • 74
    • 84869616379 scopus 로고    scopus 로고
    • Fármacos modificadores de la enfermedad
    • Ramos NF, Lom OH (eds.). México, D.F.: El Manual Moderno;
    • Ramos NF. Fármacos modificadores de la enfermedad. En: Reumatología: Diagnóstico y Tratamiento. Ramos NF, Lom OH (eds.). México, D.F.: El Manual Moderno; 2008, p. 503-521
    • (2008) Reumatología: Diagnóstico Y Tratamiento , pp. 503-521
    • Ramos, N.F.1
  • 75
    • 0030068055 scopus 로고    scopus 로고
    • Tumor necrosis factors: Pivotal components of pregnancy?
    • Hunt JS, Chen HL, Miller L. Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod 1996; 54: 554-562
    • (1996) Biol Reprod , vol.54 , pp. 554-562
    • Hunt, J.S.1    Chen, H.L.2    Miller, L.3
  • 76
    • 0034754223 scopus 로고    scopus 로고
    • Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: A recombinant fusion anticytokine treatment for rheumatoid arthritis
    • Sills ES, Perlor M, Tucker MJ, Kaplan CR, Palermo GD. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anticytokine treatment for rheumatoid arthritis. Am J Rreprod Immunol 2001; 46: 366-368
    • (2001) Am J Rreprod Immunol , vol.46 , pp. 366-368
    • Sills, E.S.1    Perlor, M.2    Tucker, M.J.3    Kaplan, C.R.4    Palermo, G.D.5
  • 78
    • 34047178478 scopus 로고    scopus 로고
    • Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy
    • Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695-698
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 695-698
    • Roux, C.H.1    Brocq, O.2    Breuil, V.3    Albert, C.4    Euller-Ziegler, L.5
  • 79
    • 33646443354 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha inhibition and VATER association: A causal relationship
    • Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006; 33: 1014-1017
    • (2006) J Rheumatol , vol.33 , pp. 1014-1017
    • Carter, J.D.1    Valeriano, J.2    Vasey, F.B.3
  • 80
    • 56749114364 scopus 로고    scopus 로고
    • A safety assessment of TNF antagonist during pregnancy: A review of the FDA database
    • Abstract
    • Carter JD, Ladhani A, Rica L, Valeriano J, Vasey FB. A safety assessment of TNF antagonist during pregnancy: a review of the FDA database. Arthritis Rheum 2007; 56 (Suppl. 9); S286. (Abstract).
    • (2007) Arthritis Rheum , vol.56 , Issue.SUPPL. 9
    • Carter, J.D.1    Ladhani, A.2    Rica, L.3    Valeriano, J.4    Vasey, F.B.5
  • 81
  • 83
    • 33746972770 scopus 로고    scopus 로고
    • Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register
    • British Society for Rheumatology Biologics Register
    • Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006; 54: 2701-2702
    • (2006) Arthritis Rheum , vol.54 , pp. 2701-2702
    • Hyrich, K.L.1    Symmons, D.P.2    Watson, K.D.3    Silman, A.J.4
  • 85
    • 33947197739 scopus 로고    scopus 로고
    • Pregnancy in women receiving anti TNF alpha therapy. Experience in Spain
    • Abstract
    • Garcia J, Joven B, Ruiz T, Moreno E, Cebrian L, Valero M, et al. Pregnancy in women receiving anti TNF alpha therapy. Experience in Spain. Annals Rheum Dis 2006; 65(Suppl. II): S317. (Abstract).
    • (2006) Annals Rheum Dis , vol.65 , Issue.SUPPL. II
    • Garcia, J.1    Joven, B.2    Ruiz, T.3    Moreno, E.4    Cebrian, L.5    Valero, M.6
  • 86
    • 64749084878 scopus 로고    scopus 로고
    • Pregnancy outcome after exposure to biologics: Results from the German Bio logics Register RABBIT
    • Abstract
    • Strangfeld A, Listing J, Rau R, Schneider M, Hierse F, Krause A, et al. Pregnancy outcome after exposure to biologics: Results from the German Bio logics Register RABBIT. Arthritis Rheum 2007; 56(Suppl. 9): S311. (Abstract).
    • (2007) Arthritis Rheum , vol.56 , Issue.SUPPL. 9
    • Strangfeld, A.1    Listing, J.2    Rau, R.3    Schneider, M.4    Hierse, F.5    Krause, A.6
  • 87
    • 23644458304 scopus 로고    scopus 로고
    • Pregnancy outcome in women who were exposed to anti-TNF alpha medications: The OTIS rheumatoid arthritis in Pregnancy Study
    • Abstract
    • Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women who were exposed to anti-TNF alpha medications: The OTIS rheumatoid arthritis in Pregnancy Study. Arthritis Rheum 2004: 50(Suppl. 9); S479. (Abstract).
    • (2004) Arthritis Rheum , vol.50 , Issue.SUPPL. 9
    • Chambers, C.D.1    Johnson, D.L.2    Jones, K.L.3
  • 88
    • 0036745041 scopus 로고    scopus 로고
    • Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study
    • Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293
    • (2002) Arthritis Rheum , vol.46 , pp. 2287-2293
    • Doran, M.F.1    Crowson, C.S.2    Pond, G.R.3    O'Fallon, W.M.4    Gabriel, S.E.5
  • 91
    • 29844444036 scopus 로고    scopus 로고
    • Vaccinate your immunocompromised patients!
    • Glück T. Vaccinate your immunocompromised patients! Rheumatology (Oxford) 2006; 45: 9-10.
    • (2006) Rheumatology (Oxford) , vol.45 , pp. 9-10
    • Glück, T.1
  • 92
    • 38449116085 scopus 로고    scopus 로고
    • Recommended adult immunization schedule: United States, October 2007-September 2008
    • Advisory Committee on Immunization Practices
    • Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med 2007; 147: 725-729
    • (2007) Ann Intern Med , vol.147 , pp. 725-729
  • 95
    • 29844450347 scopus 로고    scopus 로고
    • Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis
    • Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106-111
    • (2006) Rheumatology (Oxford) , vol.45 , pp. 106-111
    • Kapetanovic, M.C.1    Saxne, T.2    Sjöholm, A.3    Truedsson, L.4    Jönsson, G.5    Geborek, P.6
  • 96
    • 34047190402 scopus 로고    scopus 로고
    • Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients
    • DOI 10.1093/rheumatology/kel366
    • Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 608-611 (Pubitemid 46523304)
    • (2007) Rheumatology , vol.46 , Issue.4 , pp. 608-611
    • Kapetanovic, M.C.1    Saxne, T.2    Nilsson, J.-A.3    Geborek, P.4
  • 97
    • 33846954345 scopus 로고    scopus 로고
    • Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab
    • Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-279 (Pubitemid 46255742)
    • (2007) Journal of Rheumatology , vol.34 , Issue.2 , pp. 272-279
    • Kaine, J.L.1    Kivitz, A.J.2    Birbara, C.3    Luo, A.Y.4
  • 98
    • 34248643414 scopus 로고    scopus 로고
    • Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone
    • Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-957 (Pubitemid 46774837)
    • (2007) Journal of Rheumatology , vol.34 , Issue.5 , pp. 952-957
    • Visvanathan, S.1    Keenan, G.F.2    Baker, D.G.3    Levinson, A.I.4    Wagner, C.L.5
  • 100
    • 44749086936 scopus 로고    scopus 로고
    • Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine
    • Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine Vaccine 2008; 26: 3528-3533
    • (2008) Vaccine , vol.26 , pp. 3528-3533
    • Gelinck, L.B.1    Van Der Bijl, A.E.2    Visser, L.G.3    Huizinga, T.W.4    Van Hogezand, R.A.5    Rijkers, G.T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.